guest ::
| Home > Publications database > Major Improvement in Thyroid Cancer Survival of Elderly Patients in the Nordic Countries. > print |
| Home > Publications database > Major Improvement in Thyroid Cancer Survival of Elderly Patients in the Nordic Countries. > print |
| 001 | 288782 | ||
| 005 | 20250129093114.0 | ||
| 024 | 7 | _ | |a 10.1093/ejendo/lvae015 |2 doi |
| 024 | 7 | _ | |a pmid:38436478 |2 pmid |
| 024 | 7 | _ | |a 0001-5598 |2 ISSN |
| 024 | 7 | _ | |a 0804-4643 |2 ISSN |
| 024 | 7 | _ | |a 1479-683X |2 ISSN |
| 024 | 7 | _ | |a 2053-4167 |2 ISSN |
| 024 | 7 | _ | |a altmetric:160337064 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00465 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Zitrick, František |b 0 |
| 245 | _ | _ | |a Major Improvement in Thyroid Cancer Survival of Elderly Patients in the Nordic Countries. |
| 260 | _ | _ | |a Oxford |c 2024 |b Oxford University Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1738139448_5571 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:Z999# / 2024 Mar 2;190(3):K32-K36 |
| 520 | _ | _ | |a We describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway and Sweden over a 50-year period.Population-based survival study.Relative 5-year survival data were obtained from the NORDCAN database for years 1972- 2021.In the first period 1972-76, 5-year survival in TC in Finland, Norway and Sweden was 90% or higher but a strong negative step-wise age gradient was observed which was worse for men than women. Over time survival increased and in the final period, 2017-21, survival for all women and Danish men up to age 69 years was about 90% or higher, and for men from the other countries only marginally lower. Even for older women survival reached 80%, for older men somewhat less.Age disadvantage in TC survival was for most part corrected over the 50 year period and the remaining task is to boost survival for the oldest patients. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a anaplastic cancer |2 Other |
| 650 | _ | 7 | |a metastasis |2 Other |
| 650 | _ | 7 | |a prognosis |2 Other |
| 650 | _ | 7 | |a relative survival |2 Other |
| 650 | _ | 7 | |a trends |2 Other |
| 700 | 1 | _ | |a Koskinen, Anni |b 1 |
| 700 | 1 | _ | |a Liska, Vaclav |b 2 |
| 700 | 1 | _ | |a Försti, Asta |0 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696 |b 3 |u dkfz |
| 700 | 1 | _ | |a Hemminki, Akseli |0 0000-0001-7103-8530 |b 4 |
| 700 | 1 | _ | |a Hemminki, Kari |0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865 |b 5 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1093/ejendo/lvae015 |g p. lvae015 |0 PERI:(DE-600)1485160-X |n 3 |p K32-K36 |t European journal of endocrinology |v 190 |y 2024 |x 0001-5598 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:288782 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J ENDOCRINOL : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J ENDOCRINOL : 2022 |d 2023-10-21 |
| 920 | 2 | _ | |0 I:(DE-He78)Z999-20160331 |k Z999 |l Erimitus im DKFZ |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)Z999-20160331 |k Z999 |l Erimitus im DKFZ |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)Z999-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|